We have our featured research that we're going to bring—our keynotes, our Young Investigator Awards presentations, and we're going to have some special emphasis on global health, especially relevant in terms of the COVID-19 pandemic, said Richard Kovacs, MD, FACC, clinical cardiologist and president of the American College of Cardiology (ACC).
We have our featured research that we're going to bring—our keynotes, our Young Investigator Awards presentations, and we're going to have some special emphasis on global health, especially relevant and in terms of the COVID-19 pandemic, said Richard Kovacs, MD, FACC, clinical cardiologist and president of the American College of Cardiology (ACC).
Transcript
Can you describe the process of guiding ACC to the decision of delivering a virtual program?
The American College of Cardiology came to the decision fairly early on that our annual meeting was not going to be able to be held in the current environment. So, we went through the usual Kübler-Ross stages of anger, denial, and grief, and then we thought about what could we do?
So we quickly broke down into what were the parts of the meeting, and we decided that there was a very intellectual part of the meeting with science and education, but there was also an emotional and a social part of the meeting with our ceremonies, our opening event, our convocation, and all the social interactions that go on. Then there's a business part of the meeting with our industry partners and our exhibits. We looked at how we could accomplish each of those—we decided with social distancing that it was going to be very difficult to have those social interactions, but that we could maintain part of that community aspect to the meeting.
We also felt that it was very, very necessary for us to push the science that had been developing over the course of the year forward. Finally, our fellows in training and the people who are presenting abstracts and being on the national stage for the very first time in their career, we thought that was also critically important. So, we integrated all those into our virtual meeting.
What do you think will be the scientific highlights of the program?
Certainly we're going to bring forth all of our late breaking clinical trials as part of the program. We have our featured research that we're going to bring—our keynotes, our Young Investigator Awards presentations, and we're going to have some special emphasis on global health, especially relevant and in terms of the COVID-19 pandemic. We also have some emphasis on cardio obstetrics. Our late breakers span the areas of heart failure, of revascularization, of prevention, of ischemic heart disease treatments, and so we're going to see a very broad and deep program.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024
January 8th 2025Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of Hematology (ASH) meeting.
Read More